Niagen Bioscience Reports Study Showing Niagen (NR) Boosts NAD+ Levels By 140% And Improves Clinical Markers In Werner Syndrome, Expanding Rare Disease Research Portfolio

Results demonstrated that nicotinamide riboside (NR) significantly elevated NAD+ levels and improved multiple clinical markers in people with Werner Syndrome

Niagen Bioscience expands rare disease research portfolio, supporting further investigation of NAD+ augmentation with NR as a therapeutic strategy in rare progeroid diseases

Niagen Bioscience, Inc. (NASDAQ:NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, shares positive results from a clinical study published in the peer-reviewed journal Aging Cell, by a team led by Masaya Koshizaka, M.D., Ph.D., Associate Professor, and Koutaro Yokote, M.D., Ph.D., MBA, President of Chiba University, both of the Center for Preventive Medical Sciences, Chiba University, and the Department of Diabetes, Metabolism and Endocrinology, Chiba University Hospital, Japan. This is the first study to demonstrate the safety and efficacy of Niagen Bioscience's patented nicotinamide riboside (NR) ingredient, Niagen®, in individuals with Werner syndrome (WS), a rare genetic disorder marked by rapid aging and premature mortality.

The newly published double-blind, placebo-controlled study found that daily supplementation with Niagen significantly elevated blood NAD+ levels by approximately 140% and improved multiple clinical markers of cardiovascular and skin health in individuals with WS. Affecting approximately 1 in 380,000 to 1 in 1,000,000 people globally (GeneReviews), Werner syndrome is caused by mutations that impair DNA repair, leading to cellular aging decades ahead of normal progression.